BofA has reinstated coverage of 11 large-cap pharmaceutical and biotech stocks, with Eli Lilly (LLY), Gilead (GILD) and Merck ...
Eli Lilly & Co. will begin studies to see if its blockbuster weight-loss medicines are also effective at controlling ...
The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.
With Eli Lilly's diabetes and obesity products Mounjaro and Zepbound booming in popularity, the drugmaker finds itself in a ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Weight-loss drugs could be a boon for insurers, but it is too soon to tell whether the industry will be transformed, the head of Swiss Re’s life and health reinsurance arm said.
One particular healthcare stock has shown its ability to soar on good news -- and it's had plenty of it. This year the ...
S&P 500, JPMorgan Chase & Co, Eli Lilly and Company, Novo Nordisk A/S Class B. Read Edison Group (Melanie Jenner)'s latest article on Investing.com UK.